Granite Group Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$993K Buy
3,947
+10
+0.3% +$2.15K 0.59% 33
2026
Q1
$813K Buy
3,937
+161
+4% +$35.7K 0.49% 36
2025
Q4
$863K Sell
3,776
-136
-3% -$31K 0.49% 33
2025
Q3
$906K Buy
3,912
+8
+0.2% +$1.63K 0.55% 29
2025
Q2
$725K Hold
3,904
0.44% 29
2025
Q1
$818K Sell
3,904
-4,203
-52% -$817K 0.57% 29
2024
Q4
$1.44M Buy
8,107
+34
+0.4% +$6.25K 0.92% 25
2024
Q3
$1.59M Sell
8,073
-3,967
-33% -$740K 1.02% 22
2024
Q2
$2.07M Buy
12,040
+244
+2% +$40.4K 1.56% 17
2024
Q1
$2.15M Sell
11,796
-79
-0.7% -$13.6K 1.45% 15
2023
Q4
$2.13M Buy
+11,875
New +$1.73M 1.51% 15

Other funds holding ABBV

Granite Group Advisors's ABBV Position: Q2 2026 in Review

Granite Group Advisors increased its AbbVie (ABBV) stake by 0.25% in Q2 2026, buying an estimated $2.15K and bringing the position to 3,947 shares worth $993K. The position accounts for 0.59% of the portfolio, ranked #33.

Granite Group Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.15M in Q1 2024. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Granite Group Advisors held 3,947 shares of AbbVie worth $993K as of Q2 2026.
  • Granite Group Advisors bought 10 AbbVie shares in Q2 2026, an estimated $2.15K.
  • AbbVie made up 0.59% of Granite Group Advisors's portfolio in Q2 2026, its #33 holding.
  • Granite Group Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • Granite Group Advisors's AbbVie position peaked at $2.15M in Q1 2024.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Granite Group Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.